Posted at 15:29h
in News to Know
Results from a Novartis Phase II study continue to show promise for a new class of chronic migraine prevention drugs, anti-calcitonin gene-related-peptide (CGRP) drugs. The study, which was presented at the 5th
European Headache and Migraine Trust International Congress (EHMTIC) in Glasgow, Scotland, demonstrated a significant reduction in monthly migraine days compared to placebo.